N. Lerman

Improved Mode II delamination fracture toughness of composite materials by selective placement of protein-surface treated CNT

G. Marom, H. Harel, T. Lyashenko, 2013 .

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

J. Machiels, K. Harrington, R. Mehra, 2022, Annals of Oncology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.

R. Swaby, B. Burtness, C. Tourneau, 2023, Oral oncology.